Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DNM2 | P50570 | 3/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 9/20 | 0.41 |
| ▸ | MERTK | Q12866 | 9/20 | 0.41 |
| ▸ | FLT3 | P36888 | 8/20 | 0.41 |
| ▸ | GAS6 | Q14393 | 8/20 | 0.41 |
| ▸ | AXL | P30530 | 4/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457103 | 0.81 | KMT2A (0.44) | KCNH3KMT2ADNM2TYRO3MERTK | |
| SCHEMBL11002056 | 0.80 | KMT2A (0.43) | KCNH3KMT2ADNM2TYRO3MERTK | |
| SCHEMBL10998571 | 0.80 | KMT2A (0.43) | KCNH3KMT2ADNM2TYRO3MERTK | |
| SCHEMBL3455242 | 0.79 | ULK1 (0.41) | KCNH3KMT2ADNM2TYRO3MERTK | |
| SCHEMBL11081631 | 0.78 | HCAR3 (0.48) | KCNH3TYRO3MERTKFLT3GAS6 | |
| SCHEMBL11082898 | 0.77 | HCAR3 (0.47) | TYRO3MERTKFLT3GAS6AXL | |
| SCHEMBL11081740 | 0.77 | HCAR3 (0.47) | TYRO3MERTKFLT3GAS6AXL | |
| SCHEMBL10996367 | 0.76 | TLR8 (0.43) | KMT2ATYRO3MERTKFLT3GAS6 | |
| SCHEMBL10503228 | 0.75 | DNM2 (0.44) | KCNH3KMT2ADNM2TYRO3MERTK | |
| SCHEMBL10531678 | 0.75 | DNM2 (0.44) | KCNH3KMT2ADNM2TYRO3MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | KCNH3 2586/4885KMT2A 4408/4885DNM2 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.